GlassScriptPhysician profile
Sarah E Kachman
NPI 1821467689
$5,728.08
in general payments reported to CMS, 2019-2025
27 companies · $1,222 in 2025
The $1,222 reported for 2025 was more than what 90% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $969 · 2022: $942 · 2023: $1,219 · 2024: $1,375 · 2025: $1,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,816.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $966.94 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $553.13 | 2021-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $493.28 | 2021-2024 | Xarelto |
| Amgen INC. | $469.28 | 2021-2024 | Repatha |
| Novo Nordisk INC | $379.08 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $355.18 | 2021-2025 | Farxiga, Fasenra, Brilinta |
| Merck Sharp & Dohme LLC | $324.20 | 2022-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $304.74 | 2021-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $252.98 | 2021-2024 | Gallant, Cardiomems, Allure |
| Boston Scientific Corporation | $242.47 | 2022-2025 | Watchman Flx, General - Tachy, Lux-Dx Insertable Cardiac Monitor |
| Pfizer INC. | $231.01 | 2022-2025 | |
| Daiichi Sankyo INC. | $208.87 | 2023-2025 | Injectafer |
| Actelion Pharmaceuticals US, INC. | $175.52 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| Bayer Healthcare Pharmaceuticals INC. | $165.68 | 2022-2025 | |
| Amarin Pharma, INC. | $139.99 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $87.68 | 2021-2024 | |
| Chiesi USA, INC. | $79.65 | 2021-2025 | Kengreal, Cleviprex |
| Scpharmaceuticals INC. | $77.24 | 2023-2025 | |
| Kestra Medical Technology Services, INC. | $40.00 | 2024-2025 | Assure Wcd |
| United Therapeutics Corporation | $35.70 | 2024 | Tyvaso |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $33.40 | 2023-2024 | Lifevest |
| Kiniksa Pharmaceuticals International, Plc | $32.83 | 2024 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $20.63 | 2024 | |
| Lilly USA, LLC | $17.07 | 2025 | Zepbound |
| Lundbeck LLC | $15.31 | 2021 | |
| Glaxosmithkline, LLC. | $13.19 | 2024 | Shingrix, Bexsero, Arexvy |
| Regeneron Healthcare Solutions, INC. | $13.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Kachman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.